Purification and characterization of three β-glycosidases exhibiting high glucose tolerance from Aspergillus niger ASKU28. Thongpoo P, Srisomsap C, Chokchaichamnankit D, Kitpreechavanich V, Svasti J, Kongsaeree PT*. Biosci Biotechnol Biochem. 2014;78(7):1167-76.

28 May 2014
0
0

Purification and characterization of three β-glycosidases exhibiting high glucose tolerance from Aspergillus niger ASKU28.

Thongpoo P, Srisomsap C, Chokchaichamnankit D, Kitpreechavanich V, Svasti J, Kongsaeree PT*.
Biosci Biotechnol Biochem. 2014;78(7):1167-76.

Tags

Share this

Related Posts

Characterisation of the triclosan efflux pump TriABC and its regulator TriR in Agrobacterium tumefaciens C58. Nontaleerak B, Tasnawijitwong N, Eurtivong C, Sirikanchana K, Satayavivad J, Sukchawalit R, Mongkolsuk S. Microbiol Res. 2022 Oct;263:127112. doi: 10.1016/j.micres.2022.127112. Epub 2022 Jul 4. PMID: 35810656
01 Oct 2022
0

Characterisation of the triclosan efflux pump TriABC and its regulator TriR in Agrobacterium tumefaciens C58. Nontaleerak B, Tasnawijitwong N, Eurtivong C, Sirikanchana K, Satayavivad J, Sukchawalit R, Mongkolsuk S. Microbiol Res. 2022 Oct;263:127112. doi: 10.1016/j.micres.2022.127112. Epub 2022 Jul 4. PMID: 35810656

Characterisation of the triclosan efflux pump TriABC and its regulator TriR in Agrobacterium tumefaciens C58. Nontaleerak B, Tasnawijitwong N, Eurtivong C, Sirikanchana K, Satayavivad J, Sukchawalit R, Mongkolsuk S. Microbiol Res. 2022 Oct;263:127112. doi: 10.1016/j.micres.2022.127112. Epub 2022 Jul 4. PMID: 35810656
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More